Daoming Bai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daoming Bai has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Xu Zhang
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China
3 shared publications Mengyuan Liu
Department of Otorhinolaryngology Head and Neck Surgery, the Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi China
2 shared publications- Rui Yang
Department of Otorhinolaryngology Head and Neck Surgery, the Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi China
2 shared publications - Xinyu Huang
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang China
2 shared publications Zhiqiang Zhang
Nanchang University Second Affiliated Hospital
2 shared publicationsChunping Yang
Nanchang University Second Affiliated Hospital
1 shared publication
Latest Publications
- 8 December 2025
- Published by Wiley in Immunology
- Vol. 177 (4) , 749-751
Microplastics in Allergic Rhinitis: Multimechanistic Drivers of Barrier Disruption and Immune Dysregulation
- 8 December 2025
- Published by Wiley in Immunology
- Vol. 177 (4) , 749-751
Microplastics in Allergic Rhinitis: Multimechanistic Drivers of Barrier Disruption and Immune Dysregulation
- Open Access
- 17 October 2025
- Published by Wiley
M2 Macrophage Polarization and Its Role in Nasal Diseases: Signaling Pathways and Therapeutic Implications
Macrophages—particularly alternatively activated M2 phenotypes—bridge the resolution of inflammation and tissue repair in nasal mucosal disease and allergic airway disorders. Recent advances have delineated a complex signaling architecture governing M2 polarization, including JAK/STAT (STAT6 and STAT3), PI3K/Akt/mTOR, MAPK, Notch, NF-κB, and TGF-β/Smad pathways, along with epigenetic and metabolic circuits. In chronic rhinosinusitis with nasal polyps (CRSwNP), M2 macrophages interact with epithelial and type 2 lymphoid compartments, exhibit defective bactericidal/autophagic functions, and contribute to tissue remodeling through coagulation and damage-associated signals. In allergic rhinitis and asthma, M2 programs orchestrate Th2 amplification, eosinophil recruitment, and airway remodeling, yet can also mediate resolution in appropriate contexts. We synthesize mechanistic insights and disease-specific roles, highlight therapeutic strategies that modulate M2 states, and outline outstanding gaps toward precise macrophage reprogramming in rhinologic disease.
- 17 October 2025
- Published by Wiley
Open AccessM2 Macrophage Polarization and Its Role in Nasal Diseases: Signaling Pathways and Therapeutic Implications
Macrophages—particularly alternatively activated M2 phenotypes—bridge the resolution of inflammation and tissue repair in nasal mucosal disease and allergic airway disorders. Recent advances have delineated a complex signaling architecture governing M2 polarization, including JAK/STAT (STAT6 and STAT3), PI3K/Akt/mTOR, MAPK, Notch, NF-κB, and TGF-β/Smad pathways, along with epigenetic and metabolic circuits. In chronic rhinosinusitis with nasal polyps (CRSwNP), M2 macrophages interact with epithelial and type 2 lymphoid compartments, exhibit defective bactericidal/autophagic functions, and contribute to tissue remodeling through coagulation and damage-associated signals. In allergic rhinitis and asthma, M2 programs orchestrate Th2 amplification, eosinophil recruitment, and airway remodeling, yet can also mediate resolution in appropriate contexts. We synthesize mechanistic insights and disease-specific roles, highlight therapeutic strategies that modulate M2 states, and outline outstanding gaps toward precise macrophage reprogramming in rhinologic disease.
- Open Access
- 1 April 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (2)
Bacterial lysates in allergic rhinitis and chronic rhinosinusitis: Mechanisms and clinical evidence
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are chronic inflammatory disorders of the upper airways with rising global prevalence, contributing significantly to health and socioeconomic burdens. Conventional treatments—including glucocorticoids, antibiotics, antihistamines, and leukotriene inhibitors—remain insufficient in targeting the underlying pathophysiology. Bacterial lysates (BLs), functioning as immunomodulators, activate both innate, and adaptive immune pathways, reestablish Th1/Th2 equilibrium, lower immunoglobulin E concentrations, and attenuate Th2-mediated inflammation. Emerging evidence indicates that BLs (e.g. OM-85, Broncho-Vaxom) markedly improve total nasal symptom scores in AR, suppress Th2 cytokine (IL-4 and IL-13) secretion, and reduce recurrence rates and surgical interventions in CRS. In conjunction with standard therapies, BLs enhance mucosal immune defense and contribute to sustained clinical efficacy. Following the Scale for the Assessment of Narrative Review Articles guidelines, this review critically evaluates the composition, manufacturing processes, immunoregulatory mechanisms, and clinical progress of BLs in AR and CRS, providing a conceptual framework for their clinical application.
- 1 April 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (2)
Open AccessBacterial lysates in allergic rhinitis and chronic rhinosinusitis: Mechanisms and clinical evidence
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are chronic inflammatory disorders of the upper airways with rising global prevalence, contributing significantly to health and socioeconomic burdens. Conventional treatments—including glucocorticoids, antibiotics, antihistamines, and leukotriene inhibitors—remain insufficient in targeting the underlying pathophysiology. Bacterial lysates (BLs), functioning as immunomodulators, activate both innate, and adaptive immune pathways, reestablish Th1/Th2 equilibrium, lower immunoglobulin E concentrations, and attenuate Th2-mediated inflammation. Emerging evidence indicates that BLs (e.g. OM-85, Broncho-Vaxom) markedly improve total nasal symptom scores in AR, suppress Th2 cytokine (IL-4 and IL-13) secretion, and reduce recurrence rates and surgical interventions in CRS. In conjunction with standard therapies, BLs enhance mucosal immune defense and contribute to sustained clinical efficacy. Following the Scale for the Assessment of Narrative Review Articles guidelines, this review critically evaluates the composition, manufacturing processes, immunoregulatory mechanisms, and clinical progress of BLs in AR and CRS, providing a conceptual framework for their clinical application.